MACROMOLECULAR CRYSTALLOGRAPHY OF THERAPEUTIC PROTEIN COMPLEXES

治疗性蛋白质复合物的大分子晶体学

• 批准号: 7957247
• 负责人: Z HELEN WU
• 金额: $ 1.31万
• 依托单位: BROOKHAVEN SCIENCE ASSOC-BROOKHAVEN LAB
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-07-01 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7957247
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Computer Simulation; Crystallography; Data; Drug Design; Drug Industry; Funding; Grant; Institution; Light; Medical; Pharmaceutical Chemistry; Pharmacologic Substance; Research; Research Personnel; Resources; Source; Structure; Synchrotrons; Therapeutic Agents; United States National Institutes of Health; base; meetings; novel therapeutics; programs; protein complex; renin hypertension; structural biology; therapeutic protein

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Vitae Pharmaceuticals is a structure-based, drug design company that takes an opportunistic approach to target selection where we feel we can have a significant impact in developing novel therapeutic agents to meet un-met medical needs. All of the targets that we pursue have been experimentally and clinically validated by the pharmaceutical industry and many have structural data available to initiate a structure-based program. Significant effort is then devoted internally to develop the required experimental structural biology to guide medicinal chemistry and validate the results of the associated modeling and computational efforts. This approach has been successfully applied to our renin hypertension program.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 Vitae Pharmaceuticals是一家以结构为基础的药物设计公司，它采取机会主义的方法来选择目标，我们认为我们可以在开发新型治疗药物以满足未满足的医疗需求方面产生重大影响。我们所追求的所有目标都已经过制药行业的实验和临床验证，许多目标都有结构数据可用于启动基于结构的计划。然后在内部投入大量精力开发所需的实验结构生物学，以指导药物化学并验证相关建模和计算工作的结果。这种方法已成功应用于我们的肾素高血压项目。